Journey Strategic Wealth LLC Has $836,000 Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Journey Strategic Wealth LLC boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 62.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,688 shares of the medical equipment provider's stock after buying an additional 649 shares during the period. Journey Strategic Wealth LLC's holdings in Intuitive Surgical were worth $836,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ISRG. Brighton Jones LLC increased its position in Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock worth $1,916,000 after purchasing an additional 731 shares in the last quarter. Bank Pictet & Cie Europe AG raised its holdings in Intuitive Surgical by 0.5% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock valued at $99,678,000 after buying an additional 883 shares during the period. Modern Wealth Management LLC raised its holdings in Intuitive Surgical by 15.1% in the fourth quarter. Modern Wealth Management LLC now owns 1,036 shares of the medical equipment provider's stock valued at $541,000 after buying an additional 136 shares during the period. TIAA Trust National Association raised its holdings in Intuitive Surgical by 9.9% in the fourth quarter. TIAA Trust National Association now owns 2,763 shares of the medical equipment provider's stock valued at $1,442,000 after buying an additional 248 shares during the period. Finally, Signature Estate & Investment Advisors LLC purchased a new position in Intuitive Surgical in the fourth quarter valued at approximately $343,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Wells Fargo & Company boosted their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a research note on Wednesday. Barclays dropped their price target on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Citigroup reaffirmed a "buy" rating and set a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Truist Financial boosted their price target on Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Evercore ISI upped their price objective on Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical presently has an average rating of "Moderate Buy" and an average target price of $592.05.

Intuitive Surgical Price Performance

Shares of ISRG traded up $7.25 during trading hours on Friday, hitting $495.86. 1,870,941 shares of the company were exchanged, compared to its average volume of 1,842,693. The company has a market capitalization of $177.76 billion, a PE ratio of 69.16, a PEG ratio of 5.45 and a beta of 1.64. The firm has a fifty day simple moving average of $529.86 and a 200-day simple moving average of $535.13. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The company's revenue was up 21.4% compared to the same quarter last year. During the same period last year, the company posted $1.78 EPS. Sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Activity

In other news, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the transaction, the senior vice president directly owned 907 shares of the company's stock, valued at $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $515.91, for a total transaction of $96,991.08. Following the completion of the transaction, the executive vice president directly owned 5,224 shares in the company, valued at approximately $2,695,113.84. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,798 shares of company stock valued at $3,955,331. 0.70% of the stock is currently owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.